Are you Dr. Levisetti?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 66 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4921 Parkview Pl
5th Floor, Suite C
Saint Louis, MO 63110Phone+1 314-362-3500Fax+1 314-362-4096- Is this information wrong?
Summary
- Dr. Matteo Levisetti, MD is an endocrinologist in Saint Louis, Missouri. He is currently licensed to practice medicine in Missouri.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Endocrinology, Diabetes, and Metabolism, 2000 - 2004
University of ChicagoResidency, Internal Medicine, 1998 - 2000
Johns Hopkins UniversityResidency, Surgery, 1996 - 1996
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1996
Certifications & Licensure
MO State Medical License 2004 - 2016
Publications & Presentations
PubMed
- 4 citationsModel-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor...Jason H. Williams, Chandrasekhar Udata, Bishu J Ganguly, Samantha L. Bucktrout, Tenshang Joh, Megan Shannon, Gilbert Y. Wong, Matteo Levisetti, Pamela D. Garzone, Xu Meng> ;The AAPS Journal. 2020 Jan 3
- 20 citationsImmunomodulatory activity of humanized anti–IL-7R monoclonal antibody RN168 in subjects with type 1 diabetesKevan C. Herold, Samantha L. Bucktrout, Xiao Wang, Bruce W. Bode, Stephen E. Gitelman, Peter A. Gottlieb, Jing W. Hughes, Tenshang Joh, Janet B. McGill, Jeremy Pettus,...> ;JCI Insight. 2019 Dec 19
- 50 citationsBosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.Vladimir Tesar, Kazimierz Ciechanowski, York Pei, Irina Barash, Megan Shannon, Ray Li, Jason H. Williams, Matteo Levisetti, Steven Arkin, Andreas L. Serra> ;Journal of the American Society of Nephrology. 2017 Nov 1
- Join now to see all
Press Mentions
Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 25th, 2023- Cue Biopharma, Inc. (NASDAQ:CUE) Q4 2022 Earnings Call TranscriptMarch 24th, 2023
- Henry Skinner Buys Time in the Fight Against Antimicrobial Resistance; Vertex's Michael Parini Becomes President and COO at Freeline While CFO Brian Silver Plans His ExitFebruary 19th, 2021
Grant Support
- Identification Of Novel Autoantigens In Type 1 DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2008
